Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
1.805
+0.055 (3.14%)
At close: Aug 7, 2026, 4:00 PM EDT
1.730
-0.075 (-4.16%)
After-hours: Aug 7, 2026, 7:34 PM EDT
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,539,879
Market Cap
60.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -4 | -33.33% |
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Alps Group | 93 |
| MindWalk Holdings | 77 |
| Xilio Therapeutics | 76 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Cardiff Oncology | 31 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
DWTX News
- 5 days ago - Dogwood Therapeutics Slides: Corporate presentation - Filings
- 19 days ago - Dogwood enrolls first 200 patients in HAL-CINP trial - TheFly
- 19 days ago - Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 - GlobeNewsWire
- 5 weeks ago - Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewsWire
- 5 weeks ago - Dogwood Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Dogwood begins Phase 2b extension study for Halneuron - TheFly
- 2 months ago - Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics Earnings release: Q1 2026 - Filings